Agnieszka Sawicka

Publication Activity (10 Years)

Years Active: 2023-2023
Publications (10 Years): 4

Top Topics

Prostate Cancer

Escherichia Coli

Top Venues

This page only lists publications with an associated author ORCID identifier.

Publications

Doroteja Novak, Barbara Janota, Anton Amadeus Hörmann, Agnieszka Sawicka, Marko Kroselj, Alicja Hubalewska-Dydejczyk, Melpomeni Fani, Renata Mikolajczak, Petra Kolenc, Clemens Decristoforo, Piotr Garnuszek
Development of the 99m Tc-Labelled SST 2 Antagonist TECANT-1 for a First-in-Man Multicentre Clinical Study. Pharmaceutics 15 (3) (2023)
Doroteja Novak, Barbara Janota, Anton Amadeus Hörmann, Agnieszka Sawicka, Marko Kroselj, Alicja Hubalewska-Dydejczyk, Melpomeni Fani, Renata Mikolajczak, Petra Kolenc, Clemens Decristoforo, Piotr Garnuszek
Development of the 99m Tc-Labelled SST 2 Antagonist TECANT-1 for a First-in-Man Multicentre Clinical Study. Pharmaceutics 15 (3) (2023)
Beata Paulina Rurarz, Kinga Anna Urbanek, Urszula Karczmarczyk, Joanna Raczkowska, Dominika Ewa Habrowska-Górczyńska, Marta Justyna Kozieł, Karolina Kowalska, Sławomir Kadłubowski, Agnieszka Sawicka, Michał Maurin, Agnieszka Wanda Piastowska Ciesielska, Piotr Ulański
Towards Cancer Nanoradiopharmaceuticals-Radioisotope Nanocarrier System for Prostate Cancer Theranostics Based on Radiation-Synthesized Polymer Nanogels. Cancers 15 (23) (2023)
Doroteja Novak, Barbara Janota, Anton Amadeus Hörmann, Agnieszka Sawicka, Marko Kroselj, Alicja Hubalewska-Dydejczyk, Melpomeni Fani, Renata Mikolajczak, Petra Kolenc, Clemens Decristoforo, Piotr Garnuszek
Development of the 99m Tc-Labelled SST 2 Antagonist TECANT-1 for a First-in-Man Multicentre Clinical Study. Pharmaceutics 15 (3) (2023)